GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Cyclically Adjusted PB Ratio

Epigenomics AG (Epigenomics AG) Cyclically Adjusted PB Ratio : 0.05 (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Epigenomics AG's current share price is $2.50. Epigenomics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $46.51. Epigenomics AG's Cyclically Adjusted PB Ratio for today is 0.05.

The historical rank and industry rank for Epigenomics AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

EPGNF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.6   Max: 6.18
Current: 0.03

During the past years, Epigenomics AG's highest Cyclically Adjusted PB Ratio was 6.18. The lowest was 0.03. And the median was 0.60.

EPGNF's Cyclically Adjusted PB Ratio is ranked better than
96.95% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.98 vs EPGNF: 0.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Epigenomics AG's adjusted book value per share data for the three months ended in Jun. 2023 was $2.424. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $46.51 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Epigenomics AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Epigenomics AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Cyclically Adjusted PB Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 2.52 0.84 0.22 0.16

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.12 0.16 0.06 0.08

Competitive Comparison of Epigenomics AG's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Cyclically Adjusted PB Ratio falls into.



Epigenomics AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Epigenomics AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.50/46.51
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Epigenomics AG's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=2.424/123.1404*123.1404
=2.424

Current CPI (Jun. 2023) = 123.1404.

Epigenomics AG Quarterly Data

Book Value per Share CPI Adj_Book
201309 60.118 98.983 74.790
201312 96.101 99.356 119.106
201403 98.159 99.543 121.429
201406 70.393 99.543 87.081
201409 40.976 99.823 50.548
201412 69.130 99.543 85.518
201503 42.309 99.717 52.248
201506 79.190 100.417 97.110
201509 66.122 100.417 81.085
201512 60.896 99.717 75.201
201603 45.349 100.017 55.834
201606 72.013 100.717 88.046
201609 53.304 101.017 64.978
201612 95.332 101.217 115.981
201703 82.204 101.417 99.812
201706 59.628 102.117 71.904
201709 97.130 102.717 116.442
201712 74.254 102.617 89.105
201803 56.214 102.917 67.260
201806 34.929 104.017 41.351
201809 11.762 104.718 13.831
201812 89.782 104.217 106.084
201903 75.624 104.217 89.355
201906 56.070 105.718 65.311
201909 41.675 106.018 48.406
201912 38.569 105.818 44.883
202003 23.072 105.718 26.874
202006 27.434 106.618 31.685
202009 21.741 105.818 25.300
202012 15.651 105.518 18.265
202103 13.047 107.518 14.943
202106 12.964 108.486 14.715
202109 48.229 109.435 54.269
202112 32.168 110.384 35.886
202203 25.702 113.968 27.771
202206 21.540 115.760 22.913
202209 16.867 118.818 17.481
202212 13.163 119.345 13.582
202303 5.942 122.402 5.978
202306 2.424 123.140 2.424

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Epigenomics AG  (OTCPK:EPGNF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Epigenomics AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines